NeoStem, Inc. Subsidiary, Amorcyte Inc., Announces Significant Expansion in Its Claims Granted to Protect the Use of CD34+ Cells
9/10/2012 9:08:27 AM
More...
|
Amorcyte Inc., a NeoStem, Inc. Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction
1/25/2012 10:47:43 AM
More...
|
Amorcyte Inc., a NeoStem, Inc. Company, Announces Expansion of Intellectual Property Coverage
1/10/2012 10:17:59 AM
More...
|
NeoStem, Inc. Closes Amorcyte Inc. Acquisition
10/18/2011 7:00:46 AM
More...
|
NeoStem, Inc. Provides Update on Amorcyte Inc. Clinical Progress and Reports Results for Second Quarter
8/15/2011 11:24:09 AM
More...
|
NeoStem, Inc. Signs Definitive Merger Agreement to Acquire Amorcyte Inc. in Equity Transaction
7/15/2011 5:51:00 AM
More...
|
Amorcyte Inc. Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients
12/21/2010 7:45:57 AM
More...
|
Amorcyte Inc. Granted Landmark Patent
9/13/2010 9:12:18 AM
More...
|
Amorcyte Inc. Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at American College of Cardiology Annual Scientific Session
3/30/2009 8:16:06 AM
More...
|
Amorcyte Inc. Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction
4/1/2008 11:26:20 AM
More...
|
|